Congestive Heart Failure Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Merck Sharp & Dohme LLC, Corthera

DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Congestive Heart Failure market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congestive Heart Failure Market Forecast
https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Congestive Heart Failure Market Report:
• The Congestive Heart Failure market size was valued ~6,900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In August 2021, The US FDA has approved Jardiance (empagliflozin) 10 mg, and Boehringer Ingelheim and Eli Lilly reported that it has decreased the risk of cardiovascular death as well as hospitalisation for heart failure in individuals with heart failure with reduced ejection fraction (HFrEF).
• The analysis of CHF in the 7MM draws a clear scenario which showed that the patients with HFpEF have a larger proportion (i.e., ~50%) because the heart is not severely affected but keeps on working through medication or symptomatic treatment, whereas, in the case of HFrEF, the patient's heart is majorly affected. With growing age, the pumping rate of the heart declines.
• In 2023, among all the four New York Heart Association (NYHA) Classes of heart failure, Class II accounted for around 45% of the total diagnosed heart failure cases in the 7MM.
• Maximum cases of heart failure fall in the age group of ≥ 60 years. In 2023, approximately 6.8 million cases of heart failure in the US belonged to this age group.
• In 2023, among EU4 and the UK, the largest number of heart failure cases were observed in Germany, followed by France and Spain, whereas the United Kingdom accounted for the smallest number of cases in the 7MM.
• Key Congestive Heart Failure Companies: Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, Applied Therapeutics, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Merck Sharp & Dohme LLC, Corthera, Inc., AstraZeneca, GlaxoSmithKline, Otsuka Pharma, Scios, Inc., Janssen Pharma, Pharmacosmos A/S, Pfizer, GE Healthcare, and others
• Key Congestive Heart Failure Therapies: OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), KW-3902IV, Relaxin, Dapagliflozin, GSK716155, tolvaptan, Nesiritide, Iron oligosaccharide, Rosuvastatin, atorvastatin, 123I-mIBG, and others
• The Congestive Heart Failure epidemiology based on gender heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age compared to men
• The Congestive Heart Failure market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congestive Heart Failure pipeline products will significantly revolutionize the Congestive Heart Failure market dynamics.

Congestive Heart Failure Overview
Congestive heart failure (CHF), often simply referred to as heart failure, is a chronic medical condition in which the heart's ability to pump blood efficiently is compromised. This results in inadequate blood flow to meet the body's oxygen and nutrient demands, leading to a variety of symptoms and potential complication

Get a Free sample for the Congestive Heart Failure Market Report
https://www.delveinsight.com/report-store/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Congestive Heart Failure Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congestive Heart Failure Epidemiology Segmentation:
The Congestive Heart Failure market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Congestive Heart Failure
• Prevalent Cases of Congestive Heart Failure by severity
• Gender-specific Prevalence of Congestive Heart Failure
• Diagnosed Cases of Episodic and Chronic Congestive Heart Failure
Download the report to understand which factors are driving Congestive Heart Failure epidemiology trends @ Congestive Heart Failure Epidemiology Forecast
https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Congestive Heart Failure Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congestive Heart Failure market or expected to get launched during the study period. The analysis covers Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Congestive Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congestive Heart Failure Therapies and Key Companies
• OPC-61815: Otsuka pharmaceuticals
• Omecamtivmecarbil: Cytokinetics
• AZD4831: AstraZeneca
• AT-001: Applied Therapeutics
• Rexlemestrocel-L (Revascor): Mesoblast
• Finerenone (Kerendia): Bayer
• Finerenone (Kerendia): Novo Nordisk
• Sotagliflozin: Lexicon Pharmaceuticals
• Furoscix(furosemide injection): scPharmaceuticals
• KW-3902IV: Merck Sharp & Dohme LLC
• Relaxin: Corthera, Inc.
• Dapagliflozin: AstraZeneca
• GSK716155: GlaxoSmithKline
• tolvaptan: Otsuka Pharma
• nesiritide: Scios, Inc.
• Nesiritide: Janssen Pharma
• Iron oligosaccharide: Pharmacosmos A/S
• Rosuvastatin: AstraZeneca
• atorvastatin: Pfizer
• 123I-mIBG: GE Healthcare

Discover more about therapies set to grab major Congestive Heart Failure market share @ Congestive Heart Failure Treatment Market
https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Congestive Heart Failure Market Drivers
• Robust emerging Congestive Heart Failure pipeline
• Recent approval of therapies and promising emerging therapies
• Evidence-based therapies
• Aging of the population
• Rising prevalence of the disease

Congestive Heart Failure Market Barriers
• Availability of generic and off-label therapies in the market setting
• Lack of confidence in diagnosis and management
• Treatment failure to stimulate and follow society's goals and requirements

Scope of the Congestive Heart Failure Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Congestive Heart Failure Companies: Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, Applied Therapeutics, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Merck Sharp & Dohme LLC, Corthera, Inc., AstraZeneca, GlaxoSmithKline, Otsuka Pharma, Scios, Inc., Janssen Pharma, Pharmacosmos A/S, Pfizer, GE Healthcare, and others
• Key Congestive Heart Failure Therapies: OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), KW-3902IV, Relaxin, Dapagliflozin, GSK716155, tolvaptan, Nesiritide, Iron oligosaccharide, Rosuvastatin, atorvastatin, 123I-mIBG, and others
• Congestive Heart Failure Therapeutic Assessment: Congestive Heart Failure current marketed and Congestive Heart Failure emerging therapies
• Congestive Heart Failure Market Dynamics: Congestive Heart Failure market drivers and Congestive Heart Failure market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Congestive Heart Failure Unmet Needs, KOL's views, Analyst's views, Congestive Heart Failure Market Access and Reimbursement

To know more about Congestive Heart Failure companies working in the treatment market, visit @ Congestive Heart Failure Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Congestive Heart Failure Market Report Introduction
2. Executive Summary for Congestive Heart Failure
3. SWOT analysis of Congestive Heart Failure
4. Congestive Heart Failure Patient Share (%) Overview at a Glance
5. Congestive Heart Failure Market Overview at a Glance
6. Congestive Heart Failure Disease Background and Overview
7. Congestive Heart Failure Epidemiology and Patient Population
8. Country-Specific Patient Population of Congestive Heart Failure
9. Congestive Heart Failure Current Treatment and Medical Practices
10. Congestive Heart Failure Unmet Needs
11. Congestive Heart Failure Emerging Therapies
12. Congestive Heart Failure Market Outlook
13. Country-Wise Congestive Heart Failure Market Analysis (2020-2034)
14. Congestive Heart Failure Market Access and Reimbursement of Therapies
15. Congestive Heart Failure Market Drivers
16. Congestive Heart Failure Market Barriers
17. Congestive Heart Failure Appendix
18. Congestive Heart Failure Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Congestive Heart Failure Epidemiology https://www.delveinsight.com/report-store/congestive-heart-failure-chf-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Congestive Heart Failure Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Congestive Heart Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Paroxysmal Nocturnal Hemoglobinuria Pipeline
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Paroxysmal Nocturnal Hemoglobinuria market. A detailed picture of the Paroxysmal Nocturnal Hemoglobinuria pipeline landscape is provided, which includes the disease overview and Paroxysmal Nocturnal Hemoglobinuria treatment guidelines.
Paroxysmal Nocturnal Hemoglobinuria Epidemiology
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Paroxysmal Nocturnal Hemoglobinuria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dermatitis Seborrheic Market https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastro Intestinal Bleeding Market https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
DelveInsight's "Gastro Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastro Intestinal Bleeding, historical and forecasted epidemiology as well as the Gastro Intestinal Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.